Whilst KN-62 treatment does not result in apoptosis in cancer cell lines, it induces differentiation in AML cell lines [150], suppresses hypoxia inducible factor (HIF)-1α in hepatoma cells [151], potentiates the effects of etoposide in head and neck squamous cell carcinoma [152] and AML cell lines [153], and reverses adriamycin resistance in human ovarian cancer cells [154], indicating that it may be useful when combined with additional therapies. Here, HIF1A is linked to acute myeloid leukemia.